1. Introduction {#s0005}
===============

Hepatitis B virus X protein (HBx, 154 residues) is a multifunctional protein that is essential for viral replication and the development of liver diseases, such as hepatocellular carcinoma (HCC) [@bib1], [@bib2]. HBx possesses a regulatory domain at the N-terminus and a transactivation domain at the C-terminus [@bib3]. HBx interacts directly with many host proteins through functional regions or motifs [@bib4], [@bib5], [@bib6]. For example, a BH3-like motif of HBx interacts with anti-apoptotic Bcl-2 family proteins (e.g., Bcl-2 and Bcl-x~L~) that are important regulators of apoptotic cell death [@bib7], [@bib8]. This interaction between HBx and anti-apoptotic Bcl-2 family proteins results in elevated cytosolic calcium levels, efficient viral DNA replication and apoptosis.

Many structural studies of the BH3 peptide/Bcl-2 (or Bcl-x~L~) complex have demonstrated that the BH3 peptides form an amphipathic α-helix and hydrophobic residues of the BH3 peptides fit into a common hydrophobic groove of Bcl-2 or Bcl-x~L~ [@bib9], [@bib10], [@bib11], [@bib12], [@bib13]. Recently, Jiang *et al.* reported the structure of the HBx BH3-like motif (residues 110--135)/Bcl-2 complex and revealed that, similar to other BH3 peptides, the HBx BH3-like motif binds to the common hydrophobic groove of Bcl-2, but in a unique manner [@bib14]. In addition, the BH3-like motif of HBx (26 residues) has a remarkably reduced binding affinity (*K*~d~=\~193 µM) to Bcl-2 [@bib14] when compared with the binding affinities of other BH3 peptides to Bcl-x~L~, such as Bak (16 residues, *K*~d~=\~0.34 µM) [@bib9], Bad (25 residues, *K*~d~=\~0.0006 µM) [@bib10], Beclin-1 (28 residues, *K*~d~=\~1.4 µM) [@bib12] and PUMA (25 residues, *K*~d~=\~0.003 µM) [@bib13]. On the other hand, it is still unclear whether the BH3-like motif of HBx also binds to Bcl-x~L~ in a similar manner, as observed in the HBx BH3-like motif/Bcl-2 complex structure. Therefore, we are focusing on structural studies of the interaction between the HBx BH3-like motif and Bcl-x~L~.

For structural studies of protein--protein and protein--peptide interactions, fusion proteins have often been used because these fusion proteins can form stable complexes that facilitate sample preparation and structural analysis [@bib12], [@bib15], [@bib16]. In these fusion proteins, two molecules A and B are covalently connected by a flexible linker, such as consecutive glycine and serine (GS) dipeptides [@bib12], [@bib15]. For example, the Beclin-1 BH3 motif and Bcl-x~L~ have been covalently linked by five repeats of the GS dipeptide, and the 1:1 complex structure was determined by NMR [@bib12], whereas the neuropilin-1 b1 domain and VEGF-A heparin binding domain were covalently linked by three repeats of the GS dipeptide, and the structure of this complex was solved at 2.65 Å resolution by X-ray crystallography [@bib15]. Thus, the fusion protein strategy provides a powerful tool for structural studies of protein--protein and protein--peptide interactions.

In this study, we designed, purified and characterized a fusion protein of the HBx BH3-like motif and Bcl-x~L~ connected with five repeats of the GS dipeptide, HBx BH3-like motif-linker-Bcl-x~L~ ([Fig. 1](#f0005){ref-type="fig"}). The BH3-like motif consists of residues 101--136 of HBx [@bib17], and residue sequences 1--44 and 85--196 of Bcl-x~L~ were used [@bib12]. This fusion protein was successfully expressed in *E. coli* cells and purified by metal affinity and anion exchange chromatographies. Here, we demonstrate that the HBx BH3-like motif-linker-Bcl-x~L~ fusion protein should be suitable for structural studies of this complex.Fig. 1(A) Schematic representation of HBx(101−136)-(GS)~5~-Bcl-x~L~ fusion protein used in this study. (B) Amino acid sequence of the fusion protein. The first sequence of underlined residues is the His~6~-tag and the second sequence of underlined residues is the thrombin cleavage site. The rectangle indicates the five-repeat GS dipeptide linker. The sequence of HBx(101−136) is shown in bold. Bcl-x~L~ in this fusion protein lacks residues 45--84 of a long flexible loop (shown as dashes) and residues 197--233 at the C-terminus.Fig. 1.

2. Materials and methods {#s0010}
========================

2.1. Plasmid construction of Bcl-x~L~ and HBx(101−136)-(GS)~5~-Bcl-x~L~ {#s0015}
-----------------------------------------------------------------------

The Bcl-x~L~ (residues 1--44 and 85--196) used in this study lacks residues 45--84 of a long flexible loop and residues 197--233 at the C-terminus [@bib12]. First, the gene of Bcl-x~L~(1−196) was amplified using reverse transcribed cDNA from total HeLa RNA by the SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen) as a template using the F1 forward primer (5′-GGC[CATATG]{.ul}TCTCAGAGCAACCGGGAGCTG-3′) and the R1 reverse primer (5′-GGC[CTCGAG]{.ul}TCACCCATAGAGTTCCACAAAAGTATCCCA-3′) (underlined sequences indicate the *Nde*I and *Xho*I recognition sites, respectively). The amplified PCR product of Bcl-x~L~(1−196) was digested with *Nde*I and *Xho*I, and then ligated into a pET15b vector (Novagen). The resulting plasmid was named pET15b-Bcl-x~L~(1−196). The gene of Bcl-x~L~(1−196) was verified by sequencing. Next, a deletion gene of the long loop (residues 45--84) of Bcl-x~L~(1−196) was prepared using a KOD-Plus-Mutagenesis Kit (Toyobo) with the above plasmid, pET15b-Bcl-x~L~(1−196), as a template using the primers, 5′-GCAGTAAAGCAAGCGCTGAGGGAGGCA-3′ and 5′- CTCCGATTCAGTCCCTTCTGGGGCCTC-3′. The gene lacking the long loop (residues 45--84) of Bcl-x~L~(1−196), i.e., the gene of Bcl-x~L~(residues 1--44 and 85--196), was verified by sequencing. In this report, we refer to Bcl-x~L~(residues 1--44 and 85--196) as Bcl-x~L~, and the resulting plasmid was named pET15b-Bcl-x~L~.

The gene of HBx(101−136)-(GS)~5~-Bcl-x~L~ was constructed by connecting the sequences of 101--136 of HBx and Bcl-x~L~ with five repeats of the GS dipeptide. First, the gene of (GS)~5~-Bcl-x~L~ was amplified using the pET15b-Bcl-x~L~ plasmid as a template with the F2 forward primer (5′- GGC[CATATG]{.ul}GGCAGCGGCAGCGGCAGCGGCAGCGGCAGCATGTCTCAGAGCAACCGGGAGCTG-3′) and the R1 reverse primer. Next, the gene of HBx(101−136)-(GS)~5~-Bcl-x~L~ was amplified using the above PCR product, (GS)~5~-Bcl-x~L~, as a template with the F3 forward primer (5′-GGC[CATATG]{.ul}TCAGCGATGTCAACGACCGACCTTGAGGCGTACTTCAAAGACTGTGTGTTTAAAGACTGGGAGGAGTTGGGGGAGGAGATTAGGTTAAAGGTCTTTGTACTAGGAGGCGGCAGCGGCAGCGGC-3′) and the R1 reverse primer. The amplified PCR product of HBx(101−136)-(GS)~5~-Bcl-x~L~ was digested with *Nde*I and *Xho*I, and then ligated into the pET15b vector. The resulting plasmid was named pET15b-HBx(101−136)-(GS)~5~-Bcl-x~L~. The gene of HBx(101−136)-(GS)~5~-Bcl-x~L~ was verified by sequencing.

2.2. Expression and purification of HBx(101−136)-(GS)~5~-Bcl-x~L~, Bcl-x~L~ and HBx(101−136) {#s0020}
--------------------------------------------------------------------------------------------

HBx(101−136)-(GS)~5~-Bcl-x~L~ was expressed in *E. coli* BL21(DE3) pLysS cells as a hexahistidine (His~6~)-tagged protein at the N-terminus. LB media were used to prepare a non-labeled protein. M9 minimal media containing ^15^NH~4~Cl as the sole nitrogen source was used to prepare uniformly ^15^N-labeled protein. The *E. coli* cells were grown in LB or M9 medium containing 100 µg/mL ampicillin and 17 µg/mL chloramphenicol at 30 or 37 °C until the cells reached an optical density of 0.6--0.8. The expression of the target protein was induced with 0.2 mM isopropyl β-[D]{.smallcaps}-thiogalactopyranoside for 16--20 h at 25 °C. The *E. coli* cells were harvested and stored at −25 °C until further use.

The *E. coli* expressing His~6~-HBx(101−136)-(GS)~5~-Bcl-x~L~ from 4-L culture was suspended in 120--160 mL of lysis buffer \[50 mM Tris-HCl (pH 8.0), 300 mM NaCl, 1 mM dithiothreitol (DTT), 10 mM imidazole and 10% glycerol\] supplemented with 0.5% Triton-X100 and 0.1 mg/mL lysozyme and incubated for 30--60 min at room temperature, followed by sonication. The supernatant containing the His~6~-tagged protein, which was obtained by centrifugation, was loaded onto a COSMOGEL His-accept column (3--4 mL bed volume) (Nacalai Tesque Inc.). After washing the column with 25--33 column volumes of lysis buffer, the His~6~-tagged protein was eluted with lysis buffer containing 0.5 M imidazole. The flow-through of the first column was further loaded onto the COSMOGEL His-accept column and the His~6~-tagged protein was purified as described above. The resulting protein was pooled and dialyzed against dialysis buffer \[50 mM Tris-HCl (pH 8.0), 100 mM NaCl, 1 mM DTT and 10% glycerol\] and then cleaved with thrombin overnight at 4 °C. The resulting sample contains four extra vector-derived residues (Gly-Ser-His-Met) at the N-terminus. To stop the cleavage reaction, serine protease inhibitor, Pefabloc SC (Roche), was added into the sample solution. The sample containing HBx(101−136)-(GS)~5~-Bcl-x~L~ was concentrated to approximately 5 mL by an Amicon Ultra-15 centrifugal filter unit (NMWL 3 kDa) (Merck-Millipore), and the concentrated sample was further purified with a Resource Q anion exchange column (1 mL bed volume) (GE Healthcare) by a linear gradient from 0 to 0.6 M NaCl in a buffer \[50 mM Tris-HCl (pH 8.0) and 1 mM DTT\]. Finally, the buffer was exchanged to NMR buffer \[50 mM potassium phosphate (pH 6.8), 50 mM NaCl and 1 mM DTT\] using a PD10 column (GE Healthcare).

Both non- and ^15^N-labeled Bcl-x~L~ proteins were purified using a procedure that is similar to the one used to purify HBx(101−136)-(GS)~5~-Bcl-x~L~. The Bcl-x~L~ protein contains three extra vector-derived residues (Gly-Ser-His) at the N-terminus. In addition, HBx(101−136) was purified as described previously [@bib17].

All the proteins and peptides purified were stored at −85 °C until further use. The protein or peptide concentration was determined by Nanodrop 2000 UV--Vis spectrometer (Thermo Scientific), using UV absorbance at 280 nm with the following extinction coefficients and molecular weights: HBx(101−136)-(GS)~5~-Bcl-x~L~, 43,430 M^−1^ cm^−1^ and 23.1 kDa; Bcl-x~L~, 36,440 M^−1^ cm^−1^ and 18.2 kDa; HBx(101−136), 6,990 M^−1^ cm^−1^ and 4.1 kDa.

2.3. Size exclusion chromatography {#s0025}
----------------------------------

Both HBx(101−136)-(GS)~5~-Bcl-x~L~ fusion protein (0.1 mg) and Bcl-x~L~ (0.1 mg) were applied onto a Superdex-200 (10/300 GL) gel filtration column (GE Healthcare) equilibrated with gel filtration buffer \[50 mM potassium phosphate (pH 6.8), 150 mM NaCl and 1 mM DTT\] at a flow rate of 0.5 mL min^−1^ at 4 °C. The eluate was monitored at 280 nm. The molecular weights of HBx(101−136)-(GS)~5~-Bcl-x~L~ and Bcl-x~L~ were estimated using a Gel Filtration Calibration Kit LMW (GE Healthcare): conalbumin, 75 kDa: ovalbumin, 43 kDa; carbonic anhydrase, 29 kDa; ribonuclease A, 13.7 kDa; aprotinin, 6.5 kDa.

2.4. CD spectroscopy {#s0030}
--------------------

CD spectra were measured on a JASCO-820 spectropolarimeter at 25, 35 and 45 °C with a 1-mm path length cuvette. The temperatures were selected based on the high thermal stability of the Bcl-x~L~ protein: the T~m~ values of Bcl-x~L~ (residues 1--207) are from 70--77 °C at pH 4--8 [@bib18]. CD data were recorded from 260 to 198 nm using approximately 9 µM HBx(101−136)-(GS)~5~-Bcl-x~L~ or Bcl-x~L~ in a buffer composed of 5 mM potassium phosphate (pH 6.8), 5 mM NaCl and 0.1 mM DTT. All data were obtained by the subtraction of a blank corresponding to the buffer. Mean residue molar ellipticity \[θ'\] was calculated according to the protein concentration, the number of residues in the protein and the cuvette path length. The helical contents of HBx(101−136)-(GS)~5~-Bcl-x~L~ and Bcl-x~L~ were estimated using the average of two experiments by the Chen and Yang method [@bib19], the Helix-coil model method [@bib10], [@bib20], [@bib21] and the program K2D3 [@bib22]. In the Chen and Yang method, the following equation was used:$${Helical content}\left( \% \right) = - {(\lbrack\theta ’\rbrack}_{222} + 2,340)/30,300 \times 100$$where \[θ'\]~222~ is the mean residue molar ellipticity \[θ'\] at 222 nm.

In the Helix-coil model method, the following equation was used:$${Helical content}\left( \% \right) = {(\lbrack\theta ’\rbrack}_{222} - \left\lbrack \theta ’ \right\rbrack_{coil})/({\lbrack\theta ’\rbrack}_{helix} - \left\lbrack \theta ’ \right\rbrack_{coil}) \times 100$$where \[θ'\]~helix~ and \[θ'\]~coil~ represent the mean residue molar ellipticity of a complete helix \[--42,500(1−(3/*n*)) where *n*=number of residues in the protein\] and a complete random coil (+640), respectively.

The helical contents of both molecules were also estimated by the program K2D3 [@bib22], using θ' values in a range between 200 and 240 nm.

2.5. NMR spectroscopy {#s0035}
---------------------

NMR experiments were acquired using a Bruker AVANCE III 500 spectrometer. The NMR sample contained 0.3 mM ^15^N-labeled HBx(101−136)-(GS)~5~-Bcl-x~L~, 0.3 mM ^15^N-lableled Bcl-x~L~, or 0.3 mM ^15^N-lableled Bcl-x~L~ with 0.45 mM non-labeled HBx(101−136), in NMR buffer supplemented with 0.5 mM DSS and 10% D~2~O. The 2D ^1^H--^15^N HSQC spectra [@bib23], [@bib24] were recorded with the following acquisition times 128 ms (^1^H) and 56 ms (^15^N) at 25, 35 and 45 °C. Proton chemical shifts were referenced directly to DSS at 0 ppm, and ^15^N chemical shifts were referenced indirectly to the absolute frequency ratio ^15^N/^1^H =0.101329118 [@bib25]. These data were processed using TopSpin 3.2 and analyzed by Sparky ver. 3.115 [@bib26].

3. Results and discussion {#s0040}
=========================

3.1. Construction and purification of HBx(101−136)-(GS)~5~-Bcl-x~L~ {#s0045}
-------------------------------------------------------------------

The construct of HBx(101−136)-(GS)~5~-Bcl-x~L~ used in this study contains the following features ([Fig. 1](#f0005){ref-type="fig"}). There is a His~6~-tag before HBx(101−136), and a five repeat GS dipeptide linker is located between HBx(101−136) and Bcl-x~L~(residues 1--44 and 85--196). Additionally, to remove the His~6~-tag from His~6~-HBx(101−136)-(GS)~5~-Bcl-x~L~, a thrombin cleavage site is placed between the His~6~-tag and HBx(101−136).

[Fig. 2](#f0010){ref-type="fig"} shows the SDS-PAGE result of each purification step of HBx(101−136)-(GS)~5~-Bcl-x~L~. The amount of His~6~-tagged protein obtained was 3--4 mg per liter of LB or M9 culture after purification by the COSMOGEL His-accept column (lane 3). In the SDS-PAGE analysis, the fusion protein was detected as a molecular weight of \~25 kDa, which is consistent with its theoretical molecular weight (25 kDa). After dialysis, the His~6~-tag was cleaved from His~6~-HBx(101−136)-(GS)~5~-Bcl-x~L~ by thrombin overnight digestion at 4 °C. Removal of the His~6~-tag was confirmed (lane 5), and then the resulting sample was purified using the Resource Q anion exchange column with a linear gradient from 0 to 0.6 M NaCl. The HBx(101−136)-(GS)~5~-Bcl-x~L~ fusion protein eluted at \~0.3 M NaCl and the yield of the fusion protein was \~1 mg per liter of LB or M9 culture. The pooled protein was passed through a PD10 column to exchange the buffer to NMR buffer. Finally, non- and ^15^N-labeled samples were obtained with a final yield of \~0.7 mg per liter of culture. The HBx(101−136)-(GS)~5~-Bcl-x~L~ fusion protein was purified to \>95% homogeneity, as judged by SDS-PAGE (lanes 7--9).Fig. 2SDS-PAGE analysis of the protein fractions collected at each step of purification of HBx(101−136)-(GS)~5~-Bcl-x~L~. Lane 1, molecular weight marker; lane 2, supernatant; lane 3, His~6~-HBx(101−136)-(GS)~5~-Bcl-x~L~ purified by a COSMOGEL His-accept column; lane 4, His~6~-HBx(101−136)-(GS)~5~-Bcl-x~L~ after dialysis; lane 5, HBx(101−136)-(GS)~5~-Bcl-x~L~ after cleavage of the His~6~-tag by thrombin; lane 6, HBx(101−136)-(GS)~5~-Bcl-x~L~ purified by a Resource Q anion exchange column; lanes 7--9, purified HBx(101−136)-(GS)~5~-Bcl-x~L~ (1-, 3- and 5-µg loadings, respectively).Fig. 2.

3.2. Size exclusion chromatography analysis {#s0050}
-------------------------------------------

To determine whether the purified HBx(101−136)-(GS)~5~-Bcl-x~L~ fusion protein is monomeric or forms oligomers in solution, we performed size exclusion chromatography of the fusion protein and Bcl-x~L~ ([Fig. 3](#f0015){ref-type="fig"}). HBx(101−136)-(GS)~5~-Bcl-x~L~ showed a single peak ([Fig. 3](#f0015){ref-type="fig"}A, middle), and its molecular weight was determined to be \~30.5 kDa ([Fig. 3](#f0015){ref-type="fig"}B), which is 1.3 times larger than the theoretical molecular weight (23.1 kDa) of this fusion protein. On the other hand, Bcl-x~L~ was estimated to have a molecular weight of \~22.2 kDa, which is 1.2 times larger than its theoretical molecular weight (18.2 kDa). These results suggest that the purified HBx(101−136)-(GS)~5~-Bcl-x~L~ and Bcl-x~L~ exist as monomers under these conditions. This is consistent with the results that the Beclin-1-(GS)~5~-Bcl-x~L~ fusion protein and Bcl-x~L~ were determined to be monomeric in solution based on size exclusion chromatography and analytical ultracentrifugation, respectively [@bib12], [@bib27].Fig. 3Size exclusion chromatography analysis of HBx(101−136)-(GS)~5~-Bcl-x~L~ and Bcl-x~L~ using a Superdex-200 gel filtration column. (A) The chromatographic profiles of the five standard proteins (top), HBx(101−136)-(GS)~5~-Bcl-x~L~ (middle) and Bcl-x~L~ (bottom) are shown. (B) The molecular weights of HBx(101−136)-(GS)~5~-Bcl-x~L~ (H) and Bcl-x~L~ (B) were estimated to be \~30.5 kDa and \~22.2 kDa, respectively, from the elution profiles of the standard proteins used: conalbumin (C), 75 kDa; ovalbumin (O), 43 kDa; carbonic anhydrase (CA), 29 kDa; ribonuclease A (R), 13.7 kDa; aprotinin (A), 6.5 kDa.Fig. 3.

3.3. CD analysis {#s0055}
----------------

At each temperature the CD spectra of the HBx(101−136)-(GS)~5~-Bcl-x~L~ fusion protein and Bcl-x~L~ exhibited well-defined double minima at 208 and 222 nm ([Fig. 4](#f0020){ref-type="fig"}), which is characteristic of an α-helical conformation. These results are in good agreement with the structures of Bcl-x~L~[@bib27] and the BH3-peptide/Bcl-x~L~ complex [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], both of which mainly consist of α-helices. The overall structures of the fusion protein and Bcl-x~L~ were not affected largely by high temperature, *i.e.*, 45 °C. The helical contents of the fusion protein and Bcl-x~L~ estimated by three different methods (see Materials and methods) are summarized in [Table 1](#t0005){ref-type="table"}. For example, using the program K2D3, the helical content of HBx(101−136)-(GS)~5~-Bcl-x~L~ was estimated to be 46.7% (which corresponds to 96 residues in α-helices) at 25 °C, 45.3% (93 residues in α-helices) at 35 °C and 43.3% (89 residues in α-helices) at 45 °C, while that of Bcl-x~L~ was estimated to be 51.0% (81 residues in α-helices) at 25 °C, 49.6% (79 residues in α-helices) at 35 °C and 47.8% (76 residues in α-helices) at 45 °C. The helical content of the fusion protein is lower than that of Bcl-x~L~ at each temperature and by each method. This is probably because the HBx(101−136)-(GS)~5~ part of the fusion protein adopts a non-helical conformation more than a helical conformation in this fusion protein. On the other hand, the number of residues in α-helices in the fusion protein increases by 11--15 ([Table 1](#t0005){ref-type="table"}). It should be noted that this increase in number of residues in α-helices is similar to the number of residues of the HBx BH3-like motif (17 residues from D114 to K130), which form an α-helix in the HBx BH3-like motif/Bcl-2 complex structure [@bib14]. In addition, many structures of BH3 peptides/Bcl-x~L~ have revealed that the BH3 peptides form an α-helical conformation in the Bcl-x~L~ bound state [@bib9], [@bib10], [@bib11], [@bib12], [@bib13] and that α-helix formation of the Bcl-x~L~ protein is not induced by binding the BH3 peptides [@bib9], [@bib10], [@bib11], [@bib12], [@bib13]. Therefore, these results strongly suggest that the HBx(101−136) part of the fusion protein binds to the Bcl-x~L~ part and forms an α-helix.Fig. 4CD spectra of 9 µM HBx(101−136)-(GS)~5~-Bcl-x~L~ (A) and 9 µM Bcl-x~L~ (B) in 5 mM potassium phosphate (pH 6.8), 5 mM NaCl and 0.1 mM DTT at 25 (black), 35 (blue) and 45 °C (red).Fig. 4.Table 1Estimation of the secondary structure of the HBx(101--136)-(GS)~5~-Bcl-x~L~ fusion protein and Bcl-x~L~.Table 1.Helical Content (%)α-Helical residues[a](#tblt0005-fn1){ref-type="table-fn"}25 °C35 °C45 °C25 °C35 °C45 °CChen & YangFusion protein51.349.247.110610197Bcl-x~L~57.956.254.1928986HBx(101--136)[b](#tbl1fnb2){ref-type="table-fn"}−−−141211  helix-coil modelFusion protein43.642.140.6908784Bcl-x~L~48.547.345.8777573HBx(101--136)[b](#tbl1fnb2){ref-type="table-fn"}−−−131211  K2D3Fusion protein46.745.343.3969389Bcl-x~L~51.049.647.8817976HBx(101--136)[b](#tbl1fnb2){ref-type="table-fn"}−−−151413[^1][^2]

3.4. NMR analysis {#s0060}
-----------------

To examine whether the HBx(101−136)-(GS)~5~-Bcl-x~L~ fusion protein is suitable for structural studies of the interaction between HBx(101−136) and Bcl-x~L~, we acquired NMR data of ^15^N-labeled HBx(101−136)-(GS)~5~-Bcl-x~L~ alone and ^15^N-labeled Bcl-x~L~ in the absence and presence of non-labeled HBx(101−136) at a molar ratio of 1:1.5.

[Fig. 5](#f0025){ref-type="fig"} shows the 2D ^1^H--^15^N HSQC spectra of the fusion protein at different temperatures. Most of the NMR signals of the fusion protein were broadened at 25°C, but became sharper with increasing temperature, *i.e.*, at 35 and 45 °C, indicating that structural analysis at higher temperature is feasible. In addition, the well-dispersed NMR signals indicated that the fusion protein is folded even at 45 °C. This is also demonstrated by the similar percentages of helical contents at three different temperatures revealed by the CD analysis ([Table 1](#t0005){ref-type="table"}). The NMR signals at \~110 ppm for ^15^N and \~8.6 ppm for ^1^H were observed in the 2D ^1^H--^15^N HSQC spectra of the fusion protein at 25 and 35 °C (dotted black circles in [Fig. 5](#f0025){ref-type="fig"}A and B), while corresponding signals were not observed at the same temperature in the 2D ^1^H--^15^N HSQC spectrum of the ^15^N-labeled Bcl-x~L~ in the presence of non-labeled HBx(101−136) (data not shown). This suggests that these peaks are derived from the (GS)~5~-linker portion, which is supported by the results of the Beclin-1-linker-Bcl-x~L~ fusion protein [@bib12]. In contrast, these peaks hypothesized to be from the (GS)~5~-linker portion of the fusion protein were not observed at 45 °C ([Fig. 5](#f0025){ref-type="fig"}C), presumably owing to rapid solvent exchange at this temperature.Fig. 52D ^1^H--^15^N HSQC spectra of 0.3 mM ^15^N-labeled HBx(101−136)-(GS)~5~-Bcl-x~L~ at 25 (A), 35 (B) and 45 °C (C). The NMR signals predicted to arise from the backbone amide groups of the (GS)~5~-linker are shown in dotted black circles in panels A and B.Fig. 5.

Then, we compared the 2D ^1^H--^15^N HSQC spectra of ^15^N-labeled HBx(101−136)-(GS)~5~-Bcl-x~L~ alone (red) and ^15^N-labeled Bcl-x~L~ alone (black) at 45 °C ([Fig. 6](#f0030){ref-type="fig"}). The spectrum of the fusion protein differs from that of Bcl-x~L~, suggesting that the HBx(101−136) portion binds to the Bcl-x~L~ portion in the fusion protein. To confirm this and whether the fusion protein retains the native conformation of this complex, we next compared the 2D ^1^H--^15^N HSQC spectra of ^15^N-labeled HBx(101−136)-(GS)~5~-Bcl-x~L~ alone (red) and ^15^N-labeled Bcl-x~L~ in the presence of non-labeled HBx(101−136) at a molar ratio of 1:1.5 (blue) at 45 °C ([Fig. 7](#f0035){ref-type="fig"}). As expected, the overall spectral pattern of the HBx(101−136)-(GS)~5~-Bcl-x~L~ fusion protein is similar to that of Bcl-x~L~ with non-labeled HBx(101−136), indicating that the HBx(101−136)-(GS)~5~-Bcl-x~L~ fusion protein forms an intramolecular complex and likely retains the native conformation of the complex. In addition, we could observe approximately 16--18 NMR signals (dotted black circles) and a region of broadened signals (dotted green circle) in the 2D ^1^H--^15^N HSQC spectrum of the fusion protein, whereas similar signals were not observed in the spectrum of ^15^N-labeled Bcl-x~L~ in the presence of non-labeled HBx(101−136) ([Fig. 7](#f0035){ref-type="fig"}). Therefore, these NMR signals observed in the 2D ^1^H--^15^N HSQC spectrum of the fusion protein are likely derived from the ^15^N-labeled HBx(101−136) portion of the fusion protein. Our NMR results demonstrated that the HBx(101−136)-(GS)~5~-Bcl-x~L~ fusion protein should be useful for structural studies to understand the interaction between HBx and Bcl-x~L~ in atomic detail.Fig. 6Overlaid 2D ^1^H--^15^N HSQC spectra of 0.3 mM ^15^N-labeled Bcl-x~L~ (black) and 0.3 mM ^15^N-labeled HBx(101−136)-(GS)~5~-Bcl-x~L~ (red) at 45 °C.Fig. 6.Fig. 7Overlaid 2D ^1^H--^15^N HSQC spectra of 0.3 mM ^15^N-labeled Bcl-x~L~ with 0.45 mM non-labeled HBx(101−136) (blue) and 0.3 mM ^15^N-labeled HBx(101−136)-(GS)~5~-Bcl-x~L~ (red) at 45 °C. NMR signals only observed in the spectrum of the HBx(101−136)-(GS)~5~-Bcl-x~L~ fusion protein are indicated by black and green dotted circles.Fig. 7.

HBx interacts with anti-apoptotic Bcl-2 family proteins through its BH3-like motif [@bib7], [@bib8]. The modulation of apoptotic pathways by HBx is suggested to contribute to the development of (HBV-associated) HCC [@bib5]. Therefore, the complex structure between the HBx BH3-like motif and Bcl-x~L~ might provide clues for preventing or suppressing the development of HCC. This complex structure also gives us valuable information about the protein-protein interactions involved in the network of apoptosis. The strategy using the fusion protein will be of great advantage, in particular, for understanding the recognition mechanisms of BH3 peptides/Bcl-2 family proteins having relatively weak affinities, which also play important roles in apoptosis.

4. Conclusions {#s0065}
==============

The HBx(101−136)-(GS)~5~-Bcl-x~L~ fusion protein was expressed successfully in *E. coli* cells and purified to \>95% homogeneity, as judged by SDS-PAGE analysis. The purified fusion protein behaved as a monomer in aqueous solution and formed a stable intramolecular complex. In addition, our results indicate that this fusion protein retains the native conformation of the complex of Bcl-x~L~ with the HBx BH3-like motif and that the HBx(101−136) portion of the fusion protein forms an α-helix. Taken together, HBx(101−136)-(GS)~5~-Bcl-x~L~ is a useful fusion protein for structural studies of the interaction between HBx and Bcl-x~L~.
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[^1]: The number of residues in α-helices of each protein was calculated by multiplying the helical content by the residue number of the HBx(101--136)-(GS)~5~-Bcl-x~L~ fusion protein (206 residues) or Bcl-x~L~ (159 residues).

[^2]: The number of residues in α-helices of HBx(101--136) in the Bcl-x~L~ bound state was estimated by subtraction of the number of α-helical residues of Bcl-x~L~ from that of the HBx(101--136)-(GS)~5~-Bcl-x~L~ fusion protein.
